Luxturna Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Luxturna market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to several factors, including the rising prevalence of retinal diseases, the expanding aging population, growing patient demand, advancements in gene editing research, and increased investment in biotechnology.

The growth anticipated during the forecast period can be attributed to factors such as the expansion of genetic screening programs, growing demand for personalized medicine, increased need for new medications, heightened interest in genetic cures, and a rise in approvals for innovative therapies. Key trends expected to shape this period include advancements in gene therapy, the integration of digital health solutions, technological innovations in gene delivery, the development of gene editing technologies, and the incorporation of AI-driven drug discovery.

The growing prevalence of genetic eye disorders is expected to drive the expansion of the Luxturna market. These disorders encompass a variety of inherited conditions caused by gene mutations that affect the eyes’ structure or function, leading to visual impairments such as blindness or diminished vision. The increasing incidence of these disorders can be attributed to factors such as rising genetic mutations, aging populations, better diagnostic technologies, and greater awareness of hereditary conditions. Luxturna is a gene therapy designed to treat inherited retinal diseases (IRDs) caused by mutations in the RPE65 gene. It offers a potential cure by delivering a functional version of the gene to restore vision. For example, the United Nations Development Programme (UNDP) reported in December 2023 that the number of people diagnosed with vision impairments increased from 17,478 in 2021 to 19,551 in 2022. Furthermore, more than 19,000 new diagnoses were made in just the first seven months of 2023. This rise in genetic eye disorders is driving the growth of the Luxturna market.

The increasing healthcare expenditure is also expected to contribute to the growth of the Luxturna market. Healthcare expenditure refers to the total amount spent on medical services, treatments, and products by governments, businesses, or individuals. Factors such as aging populations, advancements in medical technology, the higher prevalence of chronic diseases, and rising treatment costs are all contributing to the increase in healthcare spending. This increase in expenditure supports Luxturna by making advanced treatments such as gene therapy for rare inherited retinal diseases more accessible, as they often require specialized care and are expensive. For example, in May 2023, the UK’s Office for National Statistics reported that healthcare expenditure in the UK reached approximately $367.9 billion (£283 billion) in 2022, marking a 0.7% increase from the previous year. As healthcare expenditure rises, it will fuel the growth of the Luxturna market.

A significant trend in the Luxturna market is the increasing focus on real-world studies to demonstrate the efficacy of its gene therapies. Adeno-associated virus (AAV) vector-based gene therapy, which uses a modified virus to deliver therapeutic genes to cells, has shown promise in treating genetic diseases such as RPE65-related retinal dystrophy. In April 2023, Spark Therapeutics, a US-based biotechnology company, presented real-world data for Luxturna (voretigene neparvovec), an AAV-based gene therapy, from an observational study of 8 Belgian patients at the ARVO 2023 Annual Meeting. The study showed significant improvements in light sensitivity six months after treatment for red, blue, and white light, as well as enhancements in the visual field. Two years post-treatment, Luxturna demonstrated a mean change of -0.03 BCVA and -13.67 decibels in full-field light sensitivity threshold. However, 35% of patients experienced at least one ocular adverse event, with chorioretinal atrophic changes being the most common, observed in 13 cases.

The key player in the luxturna market is F. Hoffmann-La Roche AG.

North America was the largest region in the luxturna market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in luxturna report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the luxturna market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Luxturna is a gene therapy designed to treat patients with inherited retinal diseases caused by mutations in the RPE65 gene, which can lead to vision loss or blindness. It works by delivering a functional copy of the RPE65 gene directly into retinal cells, enabling them to produce a protein essential for vision.

The primary indications for Luxturna include treating RPE65-mediated inherited retinal disease and managing vision loss. The treatment targets genetic mutations in the RPE65 gene that lead to progressive vision deterioration and blindness. Luxturna is administered via subretinal injection to deliver a functional RPE65 gene, helping improve vision in eligible patients. The patient population includes pediatric and adult patients, as well as those with an early diagnosis. Distribution occurs through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies, with end users such as hospitals, ophthalmology clinics, specialty pharmacies, and research institutions.

The luxturna market research report is one of a series of new reports that provides luxturna market statistics, including luxturna industry global market size, regional shares, competitors with a luxturna market share, detailed luxturna market segments, market trends and opportunities, and any further data you may need to thrive in the luxturna industry. This luxturna market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The luxturna market consists of sales of diagnostic kits, ocular imaging devices, cell therapy products, ophthalmic surgical instruments, retinal imaging systems, and patient monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.